Jens Cosedis Nielsen1, Arne Johannessen2, Pekka Raatikainen3, Gerhard Hindricks4, Håkan Walfridsson5,6, Steen Michael Pehrson7, Anders Englund8, Juha Hartikainen9, Leif Spange Mortensen10, Peter Steen Hansen1. 1. Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark. 2. Gentofte University Hospital, Copenhagen, Denmark. 3. Heart Center Co. Tampere University Hospital, Tampere, Finland. 4. Leipzig University Hospital, Leipzig, Germany. 5. Department of Cardiology, Linköping University, Linköping, Sweden. 6. Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 7. Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark. 8. Department of Medicine, University Hospital, Örebro, Sweden. 9. Kuopio University Hospital, Kuopio, Finland. 10. UNI-C, Danish Information Technology Centre for Education and Research, Aarhus, Denmark.
Abstract
OBJECTIVE: The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial compared radiofrequency catheter ablation (RFA) with antiarrhythmic drug therapy (AAD) as first-line treatment for paroxysmal atrial fibrillation (AF). Endpoint of ablation was elimination of electrical activity inside pulmonary veins. We present the results of the 5-year follow-up. METHODS: This pre-specified 5-year follow-up included assessment of any AF and symptomatic AF burden by one 7-day Holter recording and quality of life (QoL) assessment, using SF-36 questionnaire physical and mental component scores. Analysis was intention-to-treat. Imputation was used to compensate for missing Holter data. RESULTS:245 of 294 patients (83%) randomised to RFA (n=125) or AAD (n=120) attended the 5-year follow-up, 227 with Holter recording. Use of class I or III AAD was more frequent in AAD group (N=61 vs 13, p<0.001). More patients in the RFA group were free from AF (126/146 (86%) vs 105/148 (71%), p=0.001, relative risk (RR) 0.82; 95% CI 0.73 to 0.93) and symptomatic AF (137/146 (94%) vs 126/148 (85%), p=0.015, χ2 test, RR 0.91; 95% CI 0.84 to 0.98) in 7-day Holter recording. AF burden was significantly lower in the RFA group (any AF: p=0.003; symptomatic AF: p=0.02). QoL scores did not differ between randomisation groups. QoL scores remained improved from baseline (both components p<0.001), and did not differ from 2-year scores. CONCLUSIONS: At 5 years, the occurrence and burden of any AF and symptomatic AF were significantly lower in the RFA group than in the AAD group. Improved QoL scores observed after 2 years persisted after 5 years without between-group differences. TRIAL REGISTRATION NUMBER: NCT00133211; Results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
RCT Entities:
OBJECTIVE: The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial compared radiofrequency catheter ablation (RFA) with antiarrhythmic drug therapy (AAD) as first-line treatment for paroxysmal atrial fibrillation (AF). Endpoint of ablation was elimination of electrical activity inside pulmonary veins. We present the results of the 5-year follow-up. METHODS: This pre-specified 5-year follow-up included assessment of any AF and symptomatic AF burden by one 7-day Holter recording and quality of life (QoL) assessment, using SF-36 questionnaire physical and mental component scores. Analysis was intention-to-treat. Imputation was used to compensate for missing Holter data. RESULTS: 245 of 294 patients (83%) randomised to RFA (n=125) or AAD (n=120) attended the 5-year follow-up, 227 with Holter recording. Use of class I or III AAD was more frequent in AAD group (N=61 vs 13, p<0.001). More patients in the RFA group were free from AF (126/146 (86%) vs 105/148 (71%), p=0.001, relative risk (RR) 0.82; 95% CI 0.73 to 0.93) and symptomatic AF (137/146 (94%) vs 126/148 (85%), p=0.015, χ2 test, RR 0.91; 95% CI 0.84 to 0.98) in 7-day Holter recording. AF burden was significantly lower in the RFA group (any AF: p=0.003; symptomatic AF: p=0.02). QoL scores did not differ between randomisation groups. QoL scores remained improved from baseline (both components p<0.001), and did not differ from 2-year scores. CONCLUSIONS: At 5 years, the occurrence and burden of any AF and symptomatic AF were significantly lower in the RFA group than in the AAD group. Improved QoL scores observed after 2 years persisted after 5 years without between-group differences. TRIAL REGISTRATION NUMBER: NCT00133211; Results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal Journal: Expert Rev Cardiovasc Ther Date: 2018-12-29
Authors: Graham Lohrmann; Albert Liu; Paul Ziegler; João Monteiro; Nathan Varberg; Rod Passman Journal: J Interv Card Electrophysiol Date: 2022-08-02 Impact factor: 1.759
Authors: Katherine S Allan; Theresa Aves; Shaunattonie Henry; Laura Banfield; J Charles Victor; Paul Dorian; Jeff S Healey; Jason G Andrade; Sandra L Carroll; Michael H McGillion Journal: CJC Open Date: 2020-04-02
Authors: Tom De Potter; Massimo Grimaldi; Henrik Kjaerulf Jensen; Josef Kautzner; Petr Neuzil; Johan Vijgen; Andrea Natale; Steen Buus Kristiansen; Peter Lukac; Petr Peichl; Vivek Y Reddy Journal: J Atr Fibrillation Date: 2021-04-30
Authors: Karl-Heinz Kuck; Dmitry S Lebedev; Evgeny N Mikhaylov; Alexander Romanov; László Gellér; Oskars Kalējs; Thomas Neumann; Karapet Davtyan; Young Keun On; Sergey Popov; Maria Grazia Bongiorni; Michael Schlüter; Stephan Willems; Feifan Ouyang Journal: Europace Date: 2021-03-08 Impact factor: 5.214
Authors: Katherine S Allan; Shaunattonie Henry; Theresa Aves; Laura Banfield; J Charles Victor; Paul Dorian; Jeff S Healey; Jason Andrade; Sandra Carroll; Michael McGillion Journal: BMJ Open Date: 2017-08-21 Impact factor: 2.692
Authors: Anna Björkenheim; Axel Brandes; Anders Magnuson; Alexander Chemnitz; Nils Edvardsson; Dritan Poçi Journal: J Am Heart Assoc Date: 2018-02-24 Impact factor: 5.501